Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
NT 20-F
Form NT 20-F - Notification of inability to timely file Form 20-F
20-F/A
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
NT 20-F
Form NT 20-F - Notification of inability to timely file Form 20-F
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
News
TYPE
HEADLINE
FILED AT
6-K
NEWTiziana Life Sciences Highlights Phase 2a INFORM-MS Topline Results and Expanded Access Program Data for Intranasal Foralumab in Non-Active Secondary Progressiv
6-K
NEWTiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast on Phase 2a INFORM-MS Results
6-K
Tiziana Life Sciences Announces Positive Phase 2a INFORM-MS Topline Results for Intranasal Foralumab
6-K/A
Prior filing information, including Exhibit 99.1, incorporated into registration statements through an amendment filed November 2, 2026
6-K
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
6-K
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto